Felicitex Therapeutics to offer 2.5 million units in planned IPO priced at $6.25 a unit
Felicitex Therapeutics, a preclinical oncology drug development company, said Thursday it expects to offer 2.5 million units in its planned initial public offering, priced at $6.25 a unit. Each unit will consist of one share of common stock and two warrants to purchase a share of common stock. The Natick, Mass.-based company has applied to list on Nasdaq under the ticker 'FLCT.' Aegis Capital Corp. is sole underwriter on the deal. Proceeds will be used for research & development and for general corporate purposes and working capital. The company is pre-revenue but focuses on therapies targeting dormant and active cancer cells. The deal comes during a meager year for IPOs, as interest rate hikes and high inflation have created volatility that has kept issuers on the sidelines. The
-Ciara Linnane
(END) Dow Jones Newswires
December 01, 2022 06:27 ET (11:27 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
, 
, 
Copyright ©2023. All rights reserved.